Phoenix Bio

NEWS

NEWS

LATEST INFORMATION

September 04, 2020

Results from Studies using PXB-mouse and PXB-cells being presented at EASL 2020

March 27, 2020

PhoenixBio’s Response to the Novel Coronavirus (COVID-19)

March 26th, 2020

Dear Valued Customers, Collaborators and Partners,

 

We are writing this letter to ensure you that the PhoenixBio Group continues to operate at full capacity and is committed to assisting our customers, collaborators and partners with their research needs during this extraordinary time.

We are monitoring, around the clock, the global outbreak of the coronavirus (COVID-19) and are taking all the appropriate measures to mitigate the potential impact of the unprecedented circumstances on our services and the health of our employees.

PXB-mouse/PXB-cells Production and Research Service Operations

  • Our main PXB-mouse/PXB-cells production facility, study service site, laboratories, and the headquarters are located in Higashi Hiroshima City in Hiroshima, Japan, which is considered to be a low-risk zone as no COVID-19 positive patients have been reported as of March 26th, 2020.
  • Our CRO partners in Japan and North America are currently operational with no disruption in their study service capacity. PhoenixBio also has a supportive PXB-mouse/PXB-cells production facility in Edmonton, Alberta, Canada.
  • There is no disruption in the import of test materials & export study service samples. Shipping & receiving is currently fully operational at all of our locations.
  • Therefore, at this moment we do not have any significant concerns in the production of both PXB-mice and PXB-cells, as well as the operations of our research services.

Business and Alliance Operations

  • Although the main functions of PhoenixBio’s Research Planning & Business Development are located in New York City, NY, USA, where the virus is widely spreading, we implemented full remote work of all the staff on March 10th, 2020, prior to the start of mass outbreak of the virus in New York City.
  • PhoenixBio also maintains marketing functions in Edmonton, Alberta, Canada with staff having remotely working since March 16th, 2020.
  • We have halted any in-person meetings at this moment and are proceeding with teleconferencing communications and consultation with our customers, collaborators and partners.
  • We are dedicated to providing full-scale business and alliance operations, while protecting the health of our customers, collaborators and partners as well as employees, under this current situation.

PhoenixBio continues to take all the necessary steps to prevent potential future infection of the COVID-19 virus to our employees and optimize the business operations under the current situation. We continue to operate at full capacity and are committed to assisting our customers, collaborators and partners with their research needs.

We thank you very much for your trust during this dynamic situation.

 

Sincerely,

PhoenixBio Co., Ltd.

President & CEO Takashi Shimada

March 12, 2020

Poster Presentations Planned for the SOT 59th Annual Meeting

February 21, 2020

PhoenixBio to support the MAM 2020

PhoenixBio is supporting the MAM 2020 as a Day Refreshments Sponsor and provides attendees with the refreshments on Tuesday, February 25 (Pre-Erythrocytic Biology session day).

MAM 2020 will feature leading experts in the field while providing opportunities for young researchers and scientists from malaria endemic countries to showcase their research through selected talks and posters from submitted abstracts.

The meeting is held from February 23 to February 27, 2020 at Mantra Lorne in Victoria, Australia.

 

December 03, 2019

PhoenixBio Receives “Top 10% most cited” Recognition from PLOS ONE

PhoenixBio is pleased to announce that “Generation of Novel Chimeric Mice with Humanized Livers by Using Hemizygous cDNA-uPA/SCID Mice” is in the top 10% most cited PLOS ONE papers published in 2015.

The paper describes the humanized liver chimeric mice (PXB-mouseR) generated on PhoenixBio’s proprietary cDNA-uPA/SCID genetic background. The newly developed cDNA-uPA/SCID background allows significant improvements in the robustness and quality of the PXB-mouseR model, which has seen increased usage in a wide range of research fields, including Viral Hepatitis, Toxicity, Drug Metabolism & Pharmacokinetics, Metabolic Liver Disease, Oligonucleotide Therapeutics, and Gene Therapy.

The recognition by PLOS ONE demonstrates the utility of the PXB-mouseR across various biomedical fields and indicates the support for the model by both academic and industrial researchers. PhoenixBio is committed to contributing to the Life Sciences and will continue working with members in the Biomedical field to further their research goals.

November 15, 2019

PhoenixBio to present its services at ACT 2019

We will be furnishing a booth at the American College of Toxicology 40th Annual Meeting & Exhibition 2019 held from November 17 to November 20, 2019 at the JW Marriott Desert Ridge in Phoenix, AZ, USA.

 

November 06, 2019

Results from Studies using PXB-Mouse and PXB-cells being presented at AASLD 2019

October 16, 2019

PhoenixBio to present its services at ESGCT 2019

We will be furnishing a booth at ESGCT 27th Annual Congress 2019 held from October 22 to October 25, 2019 at Barcelona International Convention Center in Barcelona, Spain.